Page 26 - 《中国药房》2021年10期

of real-world evidence：when real is reliable[J]. Ther In- real-world evidence for regulatory decisions[J]. Clin Phar-
nov Regul Sci，2018，52（3）：362-368. macol Ther，2019，106（1）：103-115.
[44] FDA. Summary of safety and effectiveness data（SSED） [57] LASKY T，CARLETON B，HORTON D B，et al. Real-
ventricular assist device[EB/OL].（2019-05-31）[2020-10- world evidence to assess medication safety or effective-
01]. www.accessdata.fda.gov/cdrh_docs/pdf16/P160035B. ness in children：systematic review[J]. Drugs Real World
pdf. Outcomes，2020，7（2）：97-107.
[45] FDA. New pediatric labeling information database[EB/OL]. [58] LASKY T. In the real-world，kids use medications and
[2020-09-10]. https：//www.accessdata.fda.gov/scripts/sda/ devices[J]. Drugs Real World Outcomes，2017，4（2）：1-4.
sdnavigation.cfm?sd=labelingdatabase. [59] LASKY T，ARTAMAN A，CZAJA A S，et al. Current
[46] PARK M S. Regulatory innovation for expansion of indi- needs in pediatric pharmacoepidemiology[J]. Pharmaco-
cations and pediatric drug development[J]. Transl Clin epidemiol Drug Saf，2016，25（6）：738-742.
Pharmacol，2018，26（4）：155-159. [60] DESHPANDE P R，RAJAN S，SUDEEPTHI B L，et al.
[47] 耿莹，赵德恒，杨志敏.我国儿童用药进行上市后真实世 Patient-reported outcomes：a new era in clinical research
界数据收集的考虑[J].中国新药杂志，2018，27（18）： [J]. Perspect Clin Res，2011，2（4）：137-144.
2107-2110. [61] LEAHY A B，STEINECK A. Patient-reported outcomes in
[48] VAN DRIEST S L，CHOI L. Real-world data for pediatric pediatric oncology：the patient voice as a gold standard[J].
pharmacometrics：can we upcycle clinical data for re- JAMA Pediatr，2020，174（11）：e202868.
search use?[J]. Clin Pharmacol Ther，2019，106（1）：84-86. [62] WELCH M J，LALLY R，MILLER J E，et al. The ethics
[49] VAN DRIEST S L，MARSHALL M D，HACHEY B， and regulatory landscape of including vulnerable popula-
et al. Pragmatic pharmacology：population pharmacokine- tions in pragmatic clinical trials[J]. Clin Trials，2015，12
tic analysis of fentanyl using remnant samples from chil- （5）：503-510.
dren after cardiac surgery[J]. Br J Clin Pharmacol，2016， [63] SHORE C，GEE A W，KAHN B，et al. Barriers and disin-
81（6）：1165-1174. centives to the use of real-world evidence and real-world
[50] MCMAHON A W，DAL P G. Assessing drug safety in data[M].Washington（DC）：National Academies Press
children：the role of real-world data[J]. N Engl J Med， （US），2019：39-50.
2018，378（23）：2155-2157. [64] AAP committee on bioethics. Informed consent in deci-
[51] MEADOR K J，BAKER G A，BROWNING N，et al. Fetal sion-making in pediatric practice[J]. Pediatrics，2016，138
antiepileptic drug exposure and cognitive outcomes at age （2）：e20161484.
6 years（NEAD study）：a prospective observational [65] RUDRAPATNA V A，BUTTE A J. Opportunities and chal-
study[J]. Lancet Neurol，2013，12（3）：244-252. lenges in using real-world data for health care[J]. J Clin In-
[52] OLÉN O，ASKLING J，SACHS M C，et al. Childhood on- vest，2020，130（2）：565-574.
set inflammatory bowel disease and risk of cancer：a [66] MIKSAD R A，ABERNETHY A P. Harnessing the power
Swedish nationwide cohort study 1964-2014[J]. BMJ， of real-world evidence（RWE）：a checklist to ensure regu-
2017，358：j3951. latory-grade data quality[J]. Clin Pharmacol Ther，2018，
[53] MASS D. The promises（and problems）of real world da- 103（2）：202-205.
ta[EB/OL].（2018-11-26）[2021-05-09]. https：//www.mass- [67] BEVANS K B，RILEY A W，MOON J，et al. Conceptual
device.com/the-promises-and-problems-of-real-world-data/. and methodological advances in child-reported outcomes
[54] FLEURENCE R L，FORREST C B，SHUREN J. Streng- measurement[J]. Expert Rev Pharmacoecon Outcomes
thening the evidence base for pediatric medical devices Res，2010，10（4）：385-396.
using real-world data[J]. J Pediatr，2019，214：209-211. [68] GOULOOZE S C，ZWEP L B，VOGT J E，et al. Beyond
[55] McKinsey & Company. Real-world evidence：from activity the randomized clinical trial：innovative data science to
to impact in healthcare decision making[EB/OL]. [2020- close the pediatric evidence gap[J]. Clin Pharmacol Ther，
09-09]. https：//www.mckinsey.com/industries/pharmaceu- 2020，107（4）：786-795.
ticals-and-medical-products/our-insights/real-world-evi- [69] CARPENTER D，GONZALEZ D，RETSCH-BOGART
dence-from-activity-to-impact-in-healthcare-decision-ma- G，et al. Methodological and ethical issues in pediatric
king. medication safety research[J]. Pediatrics，2017，140（3）：
[56] GATTO N M，REYNOLDS R F，CAMPBELL U B. A e20170195.
structured preapproval and postapproval comparative （收稿日期：2020-10-16 修回日期：2021-05-09）
study design framework to generate valid and transparent （编辑：孙 冰）

·1172 · China Pharmacy 2021 Vol. 32 No. 10 中国药房 2021年第32卷第10期